December 3, 2019
QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition.
The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
The poster is being shown on Saturday, December 7, from 5:30 PM to 7:30 PM at Hall B, Level 2 of Orange County Convention Center:
“A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies”
by Srikumar Sahasranaman (Clinical Pharmacology, BeiGene USA, Inc.), Oleg Demin Jr (InSysBio), Dmitry Shchelokov (InSysBio), Veronika Musatova (InSysBio), Nageshwar Budha (Clinical Pharmacology, BeiGene USA, Inc.) and Ying Ou (Clinical Pharmacology, BeiGene USA, Inc.).
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | March 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
1.
09 Mar 2017 14:10
ISBM Enclosed Conference was held
20-22 February 2017 the 10th ISBM Enclosed Conference was held. For ten years the employees annually have been meeting together to share their scientific results and talk over future plans. ISBM did a great job in this working year.
|
10
|
11
|
12
|
|
13
|
14
|
15
1.
15 Mar 2017 11:49
Institute for Systems Biology participates in American Society for Clinical Pharmacology and Therapeutics 2017 Meeting
Institute for Systems Biology Moscow – a company, providing modeling services for innovative drug design, announced participation in ASCPT 2017 Meeting, which is held on 15-18 March in Washington, DC. ISBM will present several studies and demonstrate an updated version of platform for quantitative systems pharmacology modeling of immune response - Immune Response Template (IRT).
|
16
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
1.
28 Mar 2017 17:56
Not all therapies are effective: Institute for Systems Biology Moscow to present the results of the Alzheimer’s disease Systems Pharmacology Modeling
Moscow, Russia – March 28, 2017. On the 1st April, Tatyana Karelina, ISBM leading specialist in neurodegenerative field, will present a poster entitled "Amyloid toxicity and different mechanisms of action for amyloid-targeted treatments studied by quantitative systems pharmacology model" at the 13th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders to be held on March 29 - April 2, Vienna, Austria.
|
29
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
